Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A New Paradigm Post-IASLC WCLC...
Posted: February 2017
By Melody Watson
The first plenary session on the last day of IASLC WCLC 2016 covered one of the most exciting areas in...
Letter to the Editor: Previously Excluded Patients with Autoimmune Disorders, HIV, and More
Letter to the Editor: Opening Trials to Patients Living with HIV
By Armelle Lavolé, AP-HP Hôpital Tenon, Paris, France
Posted: August 14, 2019
In response to the...
Exploring the Potential of Immuno-oncology Combination Therapy
By Cynthia L. Kryder, MS, CCC-Sp
Posted: October 2017
Editor Note: The article is part of a newly launched ongoing series about immunooncology (IO) combination therapy,...
PD-L1 Blueprint Project
Posted: February 2017
By Fred R. Hirsch, MD, PhD
In the new era of immunotherapy in thoracic cancer, evaluating PD-L1 status remains a clinical challenge. In...
Ongoing Clinical Challenges: Defining Immunotherapy Benefit for Patients With NSCLC and Poor Performance Status
This article is the first in a two-part series on ongoing challenges using immunotherapy in special populations. The second part of this series focuses on elderly...
PACIFIC Trial Leads to Durvalumab Approval in United States
The U.S. Food and Drug Administration approved durvalumab on February 16, 2018, for the treatment of patients with stage III NSCLC whose tumors are...
The CRISPR-Cas9 Toolkit: Moving From Bench to Bedside
Posted: June 2017
By Cynthia L. Kryder, MS
Decades of immunology research have shown that it is possible to harness the power of the immune system...
Ongoing Immunotherapy Challenges Part II: Defining Benefit for Elderly Patients With NSCLC
This article is the second in a two-part series on ongoing challenges using immunotherapy in special populations. The first part of this series focused on...
PD-L1 IHC Blueprint Project: Ongoing Progress Toward Consistency Among Assays
By Fred R. Hirsch, MD, PhD
Posted: April 2018
Immunotherapy is a very encouraging development in the treatment of patients with lung cancer. At this phase of...
AACR 2018: First-Line Management of Advanced NSCLC Enters New Era
By Corey Langer, MD, IASLC Lung Cancer News Editor
Posted: June 2018
The therapeutic landscape irrevocably altered on April 17, 2018, when three pivotal trials—KEYNOTE 189,...
